<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215904</url>
  </required_header>
  <id_info>
    <org_study_id>Heresco1CTIL</org_study_id>
    <secondary_id>20030312</secondary_id>
    <nct_id>NCT00215904</nct_id>
  </id_info>
  <brief_title>D-serine Adjuvant Treatment for Parkinson's Disease</brief_title>
  <official_title>D-serine Adjuvant Treatment for Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herzog Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine
      (~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced
      dyskinesias.

      D-serine will be used as add-on therapy to on-going medications received by Parkinson's
      Disease patients. The rational for this study stems from observations made in pervious
      clinical trials with schizophrenia patients, in which it was demonstrated that D-serine
      adjuvant treatment resulted in:1)improvement of parkinsonian side effects induced by
      antipsychotic drugs and 2) improvement of depression and negative (i.e apathy, blunted
      effects, anhedonia) symptoms which are similar to symptoms encountered in Parkinson's
      Disease.

      The study will have a crossover design in accordance to which each patient will receive, in
      random order D-serine and placebo for a 6 weeks period each. Thus, any participant will have
      the opportunity to receive the experimental treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UPDRS scores</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PANSS scores</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine (~2g/day)</intervention_name>
    <description>Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PD diagnosis

          -  â‰¥2 on UPDRS items 32,33

          -  receive treatment with L-dopa alone or in combination with other antiparkinsonian
             medications.

        Exclusion Criteria:

          -  current or previous history of other neurological disorders

          -  unstable medical conditions

          -  renal pathology

          -  pregnant female patients excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uriel Heresco-Levy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ezrath Nashim - Herzog Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ezrath Nashim - Herzog Memorial Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91351</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2005</study_first_submitted>
  <study_first_submitted_qc>September 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>July 5, 2012</last_update_submitted>
  <last_update_submitted_qc>July 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herzog Hospital</investigator_affiliation>
    <investigator_full_name>Heresco-Levi Uriel</investigator_full_name>
    <investigator_title>Princepal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

